Artelo Biosciences (NASDAQ:ARTL) Earns “Buy” Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Artelo Biosciences (NASDAQ:ARTL) in a research note released on Monday,Benzinga reports. D. Boral Capital currently has a $18.00 price objective on the stock.

ARTL has been the topic of a number of other research reports. Wall Street Zen downgraded shares of Artelo Biosciences to a “strong sell” rating in a report on Saturday, August 9th. D Boral Capital raised shares of Artelo Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 8th. Three investment analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Strong Buy” and an average target price of $24.00.

Artelo Biosciences Trading Down 3.2%

Artelo Biosciences stock opened at $9.58 on Monday. The company has a market capitalization of $6.71 million, a P/E ratio of -0.50 and a beta of 1.36. The firm’s fifty day simple moving average is $11.46 and its 200-day simple moving average is $8.03. Artelo Biosciences has a 1-year low of $4.92 and a 1-year high of $28.60.

Artelo Biosciences (NASDAQ:ARTL) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($5.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($5.48). On average, equities research analysts predict that Artelo Biosciences will post -2.62 earnings per share for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.